NEVVI Medicare utilization intelligence

← back

MAHMOOD, SYEDM.D. NPI 1942521216 Clinician

Hematology-Oncology · HAGERSTOWN, MD

Specialty Hematology-Oncology — from billed Medicare claims
Trained UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE — medical school, self-reported to CMS
In practice about 16 years since medical school (class of 2010, self-reported to CMS)
Location HAGERSTOWN, MD · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 64 codes billed · 80,231 disclosed volume (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
MARYLAND ONCOLOGY HEMATOLOGY PA
2020–2026
PHYSIOTHERAPY ASSOCIATES INC
2024–2025
MEDICAL PRACTICES OF ANTIETAM LLC
2019

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2018-11

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed submitted charges across all codes were in CY2024. Included with Platform.

  • Charge, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Volume Beneficiary-episodes Avg charge Avg Medicare payment
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J0185 Injection, aprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1453 Injection, fosaprepitant, 1 mg
J0461 Injection, atropine sulfate, 0.01 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
80053 Blood test, comprehensive group of blood chemicals
J0640 Injection, leucovorin calcium, per 50 mg
82784 Gammaglobulin (immune system protein) measurement
J1626 Injection, granisetron hydrochloride, 100 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J9190 Injection, fluorouracil, 500 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
83615 Lactate dehydrogenase (enzyme) level
96372 Injection of drug or substance under skin or into muscle
96375 Injection of additional new drug or substance into vein
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96413 Administration of chemotherapy into vein, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
82728 Ferritin (blood protein) level
83550 Iron binding capacity
83540 Iron level
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
83520 Measurement of substance using immunoassay technique
Q5122 Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99442 Telephone medical discussion with physician, 11-20 minutes
82378 Carcinoembryonic antigen (cea) protein level
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96523 Irrigation of implanted venous access drug delivery device
36415 Insertion of needle into vein for collection of blood sample
J7030 Infusion, normal saline solution , 1000 cc
81000 Manual urinalysis test with examination using microscope, non-automated
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96360 Infusion into a vein for hydration, 31-60 minutes
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
83735 Magnesium level
J3490 Unclassified drugs
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
86140 Measurement c-reactive protein for detection of infection or inflammation
83010 Haptoglobin (serum protein) level
96361 Infusion into a vein for hydration, each additional hour
99441 Telephone medical discussion with physician, 5-10 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
85651 Red blood cell sedimentation rate, to detect inflammation, non-automated
84100 Phosphate level
82607 Cyanocobalamin (vitamin b-12) level
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
82746 Folic acid level, serum
88184 Flow cytometry technique for dna or cell analysis, first marker
38222 Biopsy and aspiration of bone marrow sample for diagnosis
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.